Back to Trials
NCT07532603PHASE2, PHASE3Recruiting

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

Priovant Therapeutics, Inc.

Start Date

3/19/2026

Completion Date

7/31/2029

Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: 1. Age ≥ 18 years 2. Scalp biopsy consistent with LPP 3. Active and symptomatic LPP at screening and baseline- 4. Weight \> 40 kg to \< 130 kg with BMI ≤ 45 kg/m2 Exclusion Criteria: 1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer). 2. High risk of thrombosis or cardiovascular disease 3. High risk of herpes zoster 4. Active or recent infection

Interventions

DRUG

Oral Brepocitinib

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Lichen Planopilaris

Locations

Clinical Trial Site

Birmingham, Alabama 35244

United States

Clinical Trial Site

Phoenix, Arizona 85006

United States

Clinical Trial Site

Scottsdale, Arizona 85259

United States

Clinical Trial Site

Irvine, California 92617

United States

Clinical Trial Site

Oakland, California 94611

United States

Clinical Trial Site

Sacramento, California 95823

United States

Clinical Trial Site

San Francisco, California 94115

United States

Clinical Trial Site

Denver, Colorado 80237

United States

Clinical Trial Site

Farmington, Connecticut 06032

United States

Clinical Trial Site

New Haven, Connecticut 06519

United States

Clinical Trial Site

Miami, Florida 33136

United States

Clinical Trial Site

Chicago, Illinois 60611

United States

Clinical Trial Site

Skokie, Illinois 60077

United States

Clinical Trial Site

Clarksville, Indiana 47129

United States

Clinical Trial Site

Indianapolis, Indiana 46250

United States

Clinical Trial Site

Leawood, Kansas 66211

United States

Clinical Trial Site

Louisville, Kentucky 40241

United States

Clinical Trial Site

Boston, Massachusetts 02115

United States

Clinical Trial Site

Burlington, Massachusetts 01805

United States

Clinical Trial Site

Ann Arbor, Michigan 48103

United States

Clinical Trial Site

Ann Arbor, Michigan 48109

United States

Clinical Trial Site

Medina, Minnesota 55340

United States

Clinical Trial Site

Minneapolis, Minnesota 55455

United States

Clinical Trial Site

Kansas City, Missouri 66103

United States

Clinical Trial Site

Lee's Summit, Missouri 64064

United States

Clinical Trial Site

Lebanon, New Hampshire 03766

United States

Clinical Trial Site

New Hyde Park, New York 11042

United States

Clinical Trial Site

New York, New York 10451

United States

Clinical Trial Site

Durham, North Carolina 27713

United States

Clinical Trial Site

Cleveland, Ohio 44195

United States

Clinical Trial Site

Columbus, Ohio 43213

United States

Clinical Trial Site

Medina, Ohio 44256

United States

Clinical Trial Site

Portland, Oregon 97210

United States

Clinical Trial Site

Philadelphia, Pennsylvania 19104

United States

Clinical Trial Site

Charleston, South Carolina 29425

United States

Clinical Trial Site

Murfreesboro, Tennessee 37128

United States

Clinical Trial Site

Smyrna, Tennessee 37167

United States

Clinical Trial Site

Austin, Texas 78613

United States

Clinical Trial Site

Austin, Texas 78660

United States

Clinical Trial Site

Cedar Park, Texas 78613

United States

Clinical Trial Site

Prosper, Texas 75078

United States

Clinical Trial Site

Tyler, Texas 75703

United States

Clinical Trial Site

Murray, Utah 84107

United States

Clinical Trial Site

Norfolk, Virginia 23502

United States

Clinical Trial Site

Richmond, Virginia 23235

United States

Clinical Trial Site

Roanoke, Virginia 24016

United States

Clinical Trial Site

Mill Creek, Washington 98012

United States

Clinical Trial Site

Adelaide, 5074

Australia

Clinical Trial Site

Perth, 6018

Australia

Clinical Trial Site

Sydney, 2217

Australia

Clinical Trial Site

Edmonton, Alberta T6G1C3

Canada

Clinical Trial Site

Guelph, Ontario N1L0B7

Canada

Clinical Trial Site

London, Ontario M5M3Z8

Canada

Clinical Trial Site

Toronto, Ontario L4B1A5

Canada

Clinical Trial Site

Toronto, Ontario N6H5L4

Canada

Clinical Trial Site

Salford, Manchester M68HD

United Kingdom

Clinical Trial Site

Glasgow, Scotland G312ER

United Kingdom

Clinical Trial Site

Brighton, BN21ES

United Kingdom

Clinical Trial Site

London, SE19RT

United Kingdom

Clinical Trial Site

London, SW109NH

United Kingdom

Clinical Trial Site

Wrexham, LL7YP

United Kingdom